Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~Diagnosis of probable Alzheimer's disease (AD).~The participant has clinically significant symptoms of agitation secondary to AD, that interfere with daily routine and for which a prescription medication is deemed indicated, in the opinion of the investigator.~Either out-patients or residents of an assisted-living facility or a skilled nursing home.~CGI-S score is ≥ 4 (moderately ill) at screening and baseline.~Mini Mental State Examination (MMSE) score at screening between 8 and 28 (inclusive).~Caregiver who is able and willing to comply with all required study procedures, ensuring that the participant attends all study visits and takes the study medication as instructed. In order to qualify as a caregiver for this study, the individual should spend time with the participant for a minimum of 4 hours on 4 separate days per week.~Key Exclusion Criteria:~Participant has other type of dementia (e.g., vascular dementia, frontotemporal dementia, Parkinson's disease, substance-induced dementia).~Participant with co-existent clinically significant or unstable systemic diseases that could confound the interpretation of the safety results of the study (e.g. malignancy, poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, certain cardiac conduction abnormalities including QTc prolongation, or unstable valvular heart disease).~Participant with myasthenia gravis.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo during Stage 1 and Stage 2 of the study.
- AVP-923 (Type: EXPERIMENTAL): Participants will receive AVP-923-20 and AVP-923-30 in a sequential manner during Stage 1 and Stage 2 of the study.
- Placebo then AVP-923 (Type: EXPERIMENTAL): Participants will receive placebo in Stage 1 followed by AVP-923 in Stage 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).